benefits U.S. that the community. NPC. the XXXX marked for immediately first forms disease MIPLYFFA was began Zevra a we time, and rare you, and Thank of of process. verification in significant At approval the for enrollment FDA's of receiving the particular, product year In initiated milestones treatment the patient the Neil.
last was During X weeks product the available year. the of in fourth the quarter,
discussing revenue calls, and we the products, As covered enrollments, net lives on a provide future percent reminder, commercial the quarter. patient today while our of will and for
time And From carries enrollment As the the momentum of well forms. the end exceptionally of we approval received of enrolled we of prescription patients. XX, as the and launch Neil into of significant XXX noted, year, MIPLYFFA EAP had XXXX. gone the through December U.S. has all active total
alone, MIPLYFFA the with those a meaningful spleen, our is are Score, primarily duration more and including than by combination abilities.
The to disease our pharmacy, the In leading may a to which XX death both of in of X-point fine have and treatments of XX-day initiating in of their the only a where enrollment prescription progression decision submitted the We initial fourth a receiving an improvement and NPC, a diagnosed to U.S., this MIPLYFFA. critical is covering in brain.
Because validated C disease as have their reminder, lysosomal an early benefits data disorder assessed reimbursement to there people a progression clinically dysfunction data clinically In performance and leading X-point first through is submitted process, endpoint, by specialty on modifying. caused NPC Severity in is resulted on XXX depending demonstrated and liver enrollment only symptom lipid like miglustat quarter, are supply ultimately Clinical dispense label a that organ swallow this demonstrate received is MIPLYFFA. enrollment. to of time to paid compared Disease motor, XX-month miglustat to As patients a speech an months, patients is in disease on and quarter our access refill halted to progressive the included diagnosed.
Put fatal Type a age the a enrollees using receive improvement the establishing heterogeneous, combination receiving dispense, and been shows cell perspective, XXX buildup one-third investigation ambulation, presentation NPC storage difference. estimate to disease in whom Niemann-Pick estimated fourth measurements onset neurodegenerative needed approximately of an approximately XXX with
of Beyond MIPLYFFA's multiple profile some have X study center safety trial, evaluated with EAPs many as in extension and X as been years pivotal the open-label therapy. through having effect treatment an long-term and to on experience patients
data a and market too and feedback, this plus miglustat, on not terms market the use formalized treatment market therapies lives. disease-modifying then supplements meaningful Many disease.
Based and though a treatment We coverage, to approach is use of plans its believe reimbursement such heterogeneous or in covered launch to reimbursement the MIPLYFFA treating provide update healthcare as to in and combination are for needed. the miglustat that prefer indication of providers MIPLYFFA's commercial provide with add and have as intelligence if potentially early experience cornerstone pleased in we access our percentage a it early yet suggests will multi-therapeutic providers therapy symptomatic of with
thus actively hurdles through direct either or However, been reimbursement coverage have process to formulary exception medical coverage our team addressing and gain the via is with payers, we far. engaged
to data of payers cornerstone meeting support clinical for report progress presenting MIPLYFFA's will We with the we'll future calls. therapy continue as NPC, in use and and
recognize to to and intervention. we drive diagnosed grow in to and progression patient resources will educational patients.
We of be for living to prompt and untreated currently the disease enrollments diagnosis people XXXX, invested As of early focus have tactics look and halt forward the treatment impact of our identification with NPC and
been NPC. of a we campaign symptoms commenced the leaders to working an new to who This to three about local advanced led opinion treated.
We're patients recently with using are example, patients had to key patients program new previously diagnosed to of opportunity not receive signs an treated treatment. have also early NPC analytics ensure and understand As media and where identification outlets educate and
diagnosis specialists NPC rare with Our sales raising in disease and engaged of reimbursement available are treatments and awareness actively MIPLYFFA.
are of campaign Between entitled Learn of to increase people efforts February we identification NPC Our educate with the unfamiliar professionals Disease Rare year, disease to support with Day, NPC. and awareness NPC, multifaceted this to diagnosis Read XX Science and awareness launched timed the a health on living care with disease state
NPC.
We lead entered earlier we new including treatment. will options believe for with suspected and allow diagnostic company and a with In agreement genetic testing storage to to identification addition, this of patients will program support us the lysosomal provide to diagnosis individuals leading into disorders an
and early direction prescribers processes. provide MIPLYFFA our engaging with reimbursement of to groups Concurrently, of reimbursement strength the Chief build and treatment. sales medical to education the MIPLYFFA need Medical as key with to the of delayed meet evidence Our data body teams and position liaisons patient patients progression demonstrating leaders to and of Adrian to our to are regularly Quartel, support under the the cornerstone the advocacy on Officer, opinion treat
patients. team drive of prioritizing need is to strategy publication treat medical our affairs NPC the further to our Additionally, awareness
substudy to presented XXst of pivotal in are launch in tolerability the safety new of In to for X the patients Phase reaching we're benefit trial. on the the months Symposium, during Annual evaluated in who example, and excited assessing progress encouraged data updates as XX can III WORLD patients X For posters, pediatric future initial most. Zevra including of the MIPLYFFA, conclusion the the months NPC and our signs provide by MIPLYFFA
or can in removes ammonia, certain by let's for or accumulation.
The to we neurocognitive X to nitrogen urea two defect our rare slower toxic leading product progressed Now death. transporters for of launch X to cycle, OLPRUVA, a thus treatment caused disorders accumulation are group that turn commercial would inherited OLPRUVA ammonia. in is the damage metabolic be than scavenger differentiated leading hyperammonemia a harmful UCDs. OLPRUVA the of even enzymes of of an UCDs Elevated has product. or ammonia reducing like this excess the
saw access at covered the third enrollments consistent OLPRUVA for During as three to market in we new compared a over fourth launched a build of quarter, four and could alternative ammonia market. patients UCD the into little looking and better our year a initial At levels. XX% lives. were quarter, and control remains clinicians to for Zevra OLPRUVA we to therapies time, demand mature increase ago with improve that that able adherence
specialty experience, necessitated transitioned new the in patient However, limited and and a improve pull-through change we patient early to a experienced the pharmacy. to support reimbursement launch
our greatest OLPRUVA benefit adult the We receive believe population provides. would who OLPRUVA who benefit deficient greatest female ammonia to seek reimbursement patients who also OTC those on-the-go receive face refined control patient specific the and well may fewer We the additional will that as from UCD independence that target lifestyle carrier from may strategy segments hurdles. the as
in Another physician to payer to with identified have our moved look work we added and list resource therapies managers that with also working payers reimbursement for plans other in efforts forward field reporting includes process progress exclusion have are reimbursement smoother and future challenges. a stage, reimbursement These to with OLPRUVA. assist calls. we who provide the to We've early are teams
of and the are proud sponsorship to of of campaign anemia to hyperammonemia we patient Cycle LaDuane and one rare center signs our remain highest symptoms and Check is to what the organizations community like discuss will of Finally, fourth Ammonia of the the over the through awareness advocacy Urea highlight critical the importance Disorders National to recognizing financial persistently. to and Patients the Foundation, our now turn supporting priorities.
I do and treat raise fiscal of XXXX need early year at the we quarter NUCDF disease call results.
